ATE253352T1 - Verwendung einer zusammensetzung enthaltend polyether block copolymere - Google Patents

Verwendung einer zusammensetzung enthaltend polyether block copolymere

Info

Publication number
ATE253352T1
ATE253352T1 AT96925056T AT96925056T ATE253352T1 AT E253352 T1 ATE253352 T1 AT E253352T1 AT 96925056 T AT96925056 T AT 96925056T AT 96925056 T AT96925056 T AT 96925056T AT E253352 T1 ATE253352 T1 AT E253352T1
Authority
AT
Austria
Prior art keywords
polyether block
composition containing
block copolymers
containing polyether
compositions
Prior art date
Application number
AT96925056T
Other languages
English (en)
Inventor
Alexander V Kabanov
Valery Yu Alakhov
Peter G Sveshnikov
Eugenii S Severin
Original Assignee
Supratek Pharma Inc
Alexander V Kabanov
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supratek Pharma Inc, Alexander V Kabanov filed Critical Supratek Pharma Inc
Application granted granted Critical
Publication of ATE253352T1 publication Critical patent/ATE253352T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Dispersion Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
AT96925056T 1995-06-07 1996-06-07 Verwendung einer zusammensetzung enthaltend polyether block copolymere ATE253352T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/478,978 US5817321A (en) 1992-10-08 1995-06-07 Biological agent compositions
PCT/IB1996/000799 WO1996040055A2 (en) 1995-06-07 1996-06-07 Biological agent compositions

Publications (1)

Publication Number Publication Date
ATE253352T1 true ATE253352T1 (de) 2003-11-15

Family

ID=23902177

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96925056T ATE253352T1 (de) 1995-06-07 1996-06-07 Verwendung einer zusammensetzung enthaltend polyether block copolymere

Country Status (12)

Country Link
US (1) US5817321A (de)
EP (2) EP1310244A3 (de)
JP (1) JP4167299B2 (de)
CN (1) CN1192678A (de)
AT (1) ATE253352T1 (de)
AU (1) AU700021B2 (de)
BR (1) BR9609176A (de)
CA (1) CA2222776A1 (de)
DE (1) DE69630615T2 (de)
NZ (1) NZ313271A (de)
RU (1) RU2166934C2 (de)
WO (1) WO1996040055A2 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093391A (en) * 1992-10-08 2000-07-25 Supratek Pharma, Inc. Peptide copolymer compositions
US6353055B1 (en) 1994-11-18 2002-03-05 Supratek Pharma Inc. Polynucleotide compositions
US6221959B1 (en) 1994-11-18 2001-04-24 Supratek Pharma, Inc. Polynucleotide compositions
US6040295A (en) 1995-01-13 2000-03-21 Genemedicine, Inc. Formulated nucleic acid compositions and methods of administering the same for gene therapy
EP0832653A1 (de) * 1996-09-20 1998-04-01 Max-Delbrück-Centrum Für Molekulare Medizin Verwenddung von Cytokinen und cytotoxischen Substanzen in einem neuen Verfahren zur Tumorbehandlung
US20050025819A1 (en) * 1997-07-14 2005-02-03 Hayat Onyuksel Materials and methods for making improved micelle compositions
US20020115609A1 (en) * 1997-07-14 2002-08-22 Hayat Onyuksel Materials and methods for making improved micelle compositions
US5948896A (en) * 1997-08-13 1999-09-07 Gem Pharmaceuticals Processes for preparing 13-deoxy anthracycline derivatives
WO2000069942A1 (en) * 1999-05-19 2000-11-23 University Of Utah Research Foundation Stabilization and acoustic activation of polymeric micelles for drug delivery
US6713454B1 (en) * 1999-09-13 2004-03-30 Nobex Corporation Prodrugs of etoposide and etoposide analogs
AU775373B2 (en) 1999-10-01 2004-07-29 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
AU1100101A (en) * 1999-10-29 2001-05-14 Children's Hospital Of Los Angeles Bone hemostasis method and materials
US9616150B2 (en) * 1999-10-29 2017-04-11 Children's Hospital Los Angeles Bone hemostasis method and materials
IL141438A0 (en) * 2000-02-23 2002-03-10 Pfizer Prod Inc Method of increasing the bioavailability and tissue penetration of azithromycin
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US7256180B2 (en) 2000-04-28 2007-08-14 Supratek Pharma Inc. Compositions and methods for inducing activation of dendritic cells
US6338859B1 (en) * 2000-06-29 2002-01-15 Labopharm Inc. Polymeric micelle compositions
DK1313697T3 (da) 2000-08-29 2006-04-10 Nobex Corp Immunregulatoriske forbindelser, derivater deraf samt anvendelse deraf
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
SE0101702D0 (sv) 2001-05-15 2001-05-15 Ardenia Investments Ltd Novel potentiating compounds
GB0120701D0 (en) * 2001-08-24 2001-10-17 Maelor Pharmaceuticals Ltd Pharmaceutical formulations
US8048924B2 (en) 2001-08-29 2011-11-01 Biocon Limited Methods and compositions employing 4-aminophenylacetic acid compounds
WO2003034988A2 (en) * 2001-10-19 2003-05-01 Idexx Laboratories, Inc. Injectable compositions for the controlled delivery of pharmacologically active compound
HU0104790D0 (en) * 2001-11-08 2002-01-28 Human Rt Pharmaceutical combinations for topical application
GEP20063806B (en) * 2001-12-20 2006-04-25 Bristol Myers Squibb Co Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability
RU2201230C1 (ru) * 2001-12-24 2003-03-27 Закрытое акционерное общество "Брынцалов-А" Лекарственное средство флузол, обладающее противогрибковым действием
WO2003066049A1 (en) * 2002-02-06 2003-08-14 Combinatorx, Incorporated Combinations for the treatment of fungal infections
AR039744A1 (es) * 2002-06-26 2005-03-09 Alza Corp Metodos y formas de dosificacion para aumentar la solubilidad de las composiciones de farmacos para la administracion controlada
CA2494233A1 (en) * 2002-07-29 2004-02-05 Alza Corporation Formulations and dosage forms for controlled delivery of topiramate
US20050232995A1 (en) 2002-07-29 2005-10-20 Yam Nyomi V Methods and dosage forms for controlled delivery of paliperidone and risperidone
ITPD20020271A1 (it) * 2002-10-18 2004-04-19 Fidia Farmaceutici Composti chimico-farmaceutici costituiti da derivati dei taxani legati covalentemente all'acido ialuronico o ai suoi derivati.
RU2226092C1 (ru) * 2002-11-29 2004-03-27 Пятигорская государственная фармацевтическая академия Противотуберкулезные ректальные суппозитории
EP1596767B1 (de) 2003-02-12 2018-10-03 Syncera, Inc. Statistische und nichtstatistische alkylenoxid-polymer-legierungszusammensetzungen
CN1761485B (zh) * 2003-03-20 2010-04-28 日本化药株式会社 含略微水溶性抗癌剂和新型嵌段共聚物的胶束制剂
AU2004258949B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP2006528185A (ja) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
AU2004258953B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
US20050058707A1 (en) * 2003-08-06 2005-03-17 Iran Reyes Uniform delivery of topiramate over prolonged period of time with enhanced dispersion formulation
CA2535177A1 (en) 2003-08-11 2005-02-24 Advancis Pharmaceutical Corporation Robust pellet
US8062672B2 (en) 2003-08-12 2011-11-22 Shionogi Inc. Antibiotic product, use and formulation thereof
AU2004270170B2 (en) * 2003-08-29 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2538064C (en) 2003-09-15 2013-12-17 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
RU2248205C1 (ru) * 2003-09-18 2005-03-20 Открытое акционерное общество "Щелковский витаминный завод" Лекарственное средство в виде желатиновой капсулы
US20050112204A1 (en) * 2003-11-25 2005-05-26 Pfizer Inc. Pharmaceutical formulations
MXPA06007510A (es) * 2003-12-29 2009-06-10 Johnson & Johnson Composiciones de farmaco y formas de dosis novedosas de topiramato.
US20050175696A1 (en) * 2003-12-29 2005-08-11 David Edgren Drug granule coatings that impart smear resistance during mechanical compression
EP1701706A2 (de) * 2003-12-29 2006-09-20 Alza Corporation Neue arzneimittelzusammensetzungen und dosierformen
CA2572292A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
DK1773767T3 (en) 2004-07-07 2016-03-21 Biocon Ltd Synthesis of azo bound in immune regulatory relations
CN101309668A (zh) * 2005-11-30 2008-11-19 健乐克斯医药公司 经口吸收的药物制剂和用药方法
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
KR20080106176A (ko) * 2006-01-10 2008-12-04 이노베이폼 테크놀로지스 엘엘씨 농약 전달 시스템
US8148338B2 (en) * 2006-02-22 2012-04-03 Supratek Pharma Inc. Doxorubicin formulations for anti-cancer use
EP2012804A4 (de) * 2006-04-24 2012-07-04 Bruce Medical Ab Auf polymer basierende krebsmittel
US8299052B2 (en) * 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
RU2447095C2 (ru) * 2006-05-18 2012-04-10 Ниппон Каяку Кабусики Кайся Высокомолекулярный конъюгат подофиллотоксинов
BRPI0603871B8 (pt) * 2006-08-24 2021-05-25 Univ Brasilia Fundacao composições farmacêuticas para o tratamento de tripanossomíases e de doença de chagas
KR20100045508A (ko) * 2007-08-13 2010-05-03 콜리 파마슈티칼 게엠베하 특이적 면역 조절 프로필을 유도하는 규정된 뉴클레오티드간 연결의 환경에서의 ｒｎａ 서열 모티프
CA2717867C (en) 2008-03-07 2017-05-30 Paul J. Shami Activated nitric oxide donors and methods of making and using thereof
CA2717958A1 (en) * 2008-03-17 2009-09-24 University Of Utah Research Foundation Dithiocarbamate metal chelates and methods of making and using thereof
MD4009C2 (ro) * 2008-07-15 2010-08-31 Институт Химии Академии Наук Молдовы Utilizarea 1-metil-4-(N-metilaminobutil-4)-β-carbolinei în calitate de remediu antituberculos
US8445271B2 (en) 2010-05-03 2013-05-21 Enzo Life Sciences, Inc. Processes and kits for determining multi-drug resistance of cells
RU2501570C1 (ru) * 2012-05-11 2013-12-20 Федеральное государственное автономное образовательное учреждение высшего профессионального образования "Казанский (Приволжский) федеральный университет" (ФГАОУВПО КФУ) Трехфункциональные блоксополимеры этиленоксида и пропиленоксида для доставки активных веществ в живые клетки
US10792331B2 (en) * 2015-09-09 2020-10-06 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Methods for reducing cardiotoxicity from chemotherapy by administering humanin analog compositions
CN109324512A (zh) * 2018-12-05 2019-02-12 华北电力大学 一种利用已知模型信息整定降阶自抗扰控制器参数的方法
US20250295771A1 (en) 2022-05-11 2025-09-25 Celgene Corporation Methods and uses related to t cell therapy and production of same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE58981B1 (en) * 1985-10-15 1993-12-15 Vestar Inc Anthracycline antineoplastic agents encapsulated in phospholipid micellular particles
JP2517760B2 (ja) * 1989-05-11 1996-07-24 新技術事業団 水溶性高分子化医薬製剤
US5143731A (en) * 1990-08-07 1992-09-01 Mediventures Incorporated Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels
EP0619730B1 (de) * 1992-10-08 2000-12-27 Supratek Pharma Inc. Zusammensetzung von in mizellen eingeschlossenen antineoplastischen wirkstoffen

Also Published As

Publication number Publication date
CN1192678A (zh) 1998-09-09
AU6529796A (en) 1996-12-30
EP0871432A2 (de) 1998-10-21
NZ313271A (en) 2001-03-30
AU700021B2 (en) 1998-12-17
RU2166934C2 (ru) 2001-05-20
BR9609176A (pt) 1999-08-24
EP1310244A2 (de) 2003-05-14
CA2222776A1 (en) 1996-12-19
EP1310244A3 (de) 2004-01-14
EP0871432B1 (de) 2003-11-05
JPH11507619A (ja) 1999-07-06
DE69630615T2 (de) 2004-09-30
DE69630615D1 (de) 2003-12-11
US5817321A (en) 1998-10-06
WO1996040055A2 (en) 1996-12-19
JP4167299B2 (ja) 2008-10-15
WO1996040055A3 (en) 1997-04-24

Similar Documents

Publication Publication Date Title
DE69630615D1 (de) Verwendung einer zusammensetzung enthaltend polyether block copolymere
DE69617042D1 (de) Fluorhaltige, elastische copolymere, härtbare zusammensetzung und daraus hergestellte dichtungsmasse
DE3583560D1 (de) Polymerisationsverfahren und polymerzusammensetzungen.
DE68920529D1 (de) Blockcopolymere und Zusammensetzungen davon.
EP0575123A3 (de) Acethylencopolymerzusammensetzung.
AU1156688A (en) Wettable, hydrophilic, soft and oxygen permeable copolymer compositions
BR8902244A (pt) Composicao de revestimento aquosa,auto-reticulavel e polimero de vinila
FI910441A7 (fi) Alkenyylioksiryhmiä sisältäviä siloksaanikopolymeerejä, niiden valmistus ja käyttö
FI965203A0 (fi) Morfiinia, polypyrrolidonia ja polyalkyleenioksidia sisältävä koostumus
DE69113810D1 (de) (poly)sulfid enthaltende polycitraconimide und polyitaconimide.
DE3884453D1 (de) Homogene additionscopolymere von ethylen und cycloolefinmonomeren und deren herstellung.
DE59008276D1 (de) Hydrophile, quellfähige Pfropfcopolymerisate, deren Herstellung und Verwendung.
EP0918069A4 (de) Copolymer enthaltend reaktive silyl-gruppen, zusammensetzung die dieses enthält sowie verfahren zur behandlung mit demselben
EP0767185A4 (de) Acrylatcopolymer und solches enthaltende polymerzusammensetzung
DE3853340D1 (de) Dien-Blockpolymer und Polymerzusammensetzung.
AU4608089A (en) Aminated acrylate polymers
DE3680737D1 (de) Poly(etherimid-carbonat)-blockcopolymere und diese enthaltende polymermischungen.
IL142116A0 (en) Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
DE69433657D1 (de) Ethylen-Alpha-Olefin Copolymere und daraus hergestellte Formteile
DE69602178D1 (de) 2-oxo-1,3-dioxolangruppen enthaltende copolymere und daraus hergestellte beschichtungen
DE3850062D1 (de) Fluorierte Polymere und Copolymere enthaltende Perfluorpolyätherblöcke.
DE59006687D1 (de) Dispersionen von Perfluoralkylgruppen enthaltenden Copolymerisaten.
GR3019058T3 (en) 3-Arylcarbonyl-1-aminoalkyl-1H-indole containing antiglaucoma compositions
DE3587486D1 (de) Imidazolinone enthaltende polymere und copolymere.
DE69428350D1 (en) Polymere ionene als anthelminthika in tieren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties